Survey of Brigatinib for treating non-small cell lung cancer
General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
This study looks at how safe Brigatinib is for Japanese patients with non-small cell lung cancer while they take the medication as part of their regular treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Takeda Industry-sponsored |
| Drugs / interventions | birigatinib, Brigatinib |
| Locations | 1 site (Tokyo) |
| Trial ID | NCT05100069 on ClinicalTrials.gov |
What this trial studies
This observational study surveys the use of Brigatinib tablets in Japanese patients with non-small cell lung cancer. Participants will take Brigatinib according to their clinic's standard practices, while the study monitors for any side effects related to lung disease over a period of one year. The study is sponsored by Takeda, which will provide guidelines for clinics on how to record patient outcomes. The focus is on understanding the safety profile of Brigatinib in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with unresectable advanced or recurrent ALK fusion gene-positive non-small cell lung cancer.
Not a fit: Patients with a history of hypersensitivity to any component of Brigatinib may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and side effects of Brigatinib, improving treatment protocols for patients with non-small cell lung cancer.
How similar studies have performed: While this study is observational and focuses on safety, similar studies have previously shown success in understanding the effects of targeted therapies in lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer. Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
Where this trial is running
Tokyo
- Takeda Selected Site — Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: Takeda Contact
- Email: medinfoUS@takeda.com
- Phone: +1-877-825-3327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.